Trial Profile
Select A Multi-centre Randomised Prospective Open-label Study to Investigate the Efficacy & Safety of a Standardised Correction Dosage Regimen of i.v. Ferric Carboxymaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anaemia in Patients With Inflammatory Bowel Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary) ; Iron sucrose
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Acronyms FER-IBD-COR
- Sponsors Vifor
- 26 Jun 2014 New trial record